PMID,Title,Authors,Citation,First Author,Journal/Book,Publication Year,Create Date,PMCID,NIHMS ID,DOI
"33378609","Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T; COVE Study Group.","N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.","Baden LR","N Engl J Med","2021","2020/12/30","PMC7787219","","10.1056/NEJMoa2035389"
"34587382","Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine","Falsey AR, Sobieszczyk ME, Hirsch I, Sproule S, Robb ML, Corey L, Neuzil KM, Hahn W, Hunt J, Mulligan MJ, McEvoy C, DeJesus E, Hassman M, Little SJ, Pahud BA, Durbin A, Pickrell P, Daar ES, Bush L, Solis J, Carr QO, Oyedele T, Buchbinder S, Cowden J, Vargas SL, Guerreros Benavides A, Call R, Keefer MC, Kirkpatrick BD, Pullman J, Tong T, Brewinski Isaacs M, Benkeser D, Janes HE, Nason MC, Green JA, Kelly EJ, Maaske J, Mueller N, Shoemaker K, Takas T, Marshall RP, Pangalos MN, Villafana T, Gonzalez-Lopez A; AstraZeneca AZD1222 Clinical Study Group.","N Engl J Med. 2021 Dec 16;385(25):2348-2360. doi: 10.1056/NEJMoa2105290. Epub 2021 Sep 29.","Falsey AR","N Engl J Med","2021","2021/09/29","PMC8522798","","10.1056/NEJMoa2105290"
"26511519","STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies","Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, Lijmer JG, Moher D, Rennie D, de Vet HC, Kressel HY, Rifai N, Golub RM, Altman DG, Hooft L, Korevaar DA, Cohen JF; STARD Group.","BMJ. 2015 Oct 28;351:h5527. doi: 10.1136/bmj.h5527.","Bossuyt PM","BMJ","2015","2015/10/30","PMC4623764","","10.1136/bmj.h5527"
"34551225","Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase","El Sahly HM, Baden LR, Essink B, Doblecki-Lewis S, Martin JM, Anderson EJ, Campbell TB, Clark J, Jackson LA, Fichtenbaum CJ, Zervos M, Rankin B, Eder F, Feldman G, Kennelly C, Han-Conrad L, Levin M, Neuzil KM, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Polakowski L, Mascola JR, Ledgerwood JE, Graham BS, August A, Clouting H, Deng W, Han S, Leav B, Manzo D, Pajon R, Schödel F, Tomassini JE, Zhou H, Miller J; COVE Study Group.","N Engl J Med. 2021 Nov 4;385(19):1774-1785. doi: 10.1056/NEJMoa2113017. Epub 2021 Sep 22.","El Sahly HM","N Engl J Med","2021","2021/09/22","PMC8482810","NIHMS1743941","10.1056/NEJMoa2113017"
"33761206","Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120-MF59 in Adults","Gray GE, Bekker LG, Laher F, Malahleha M, Allen M, Moodie Z, Grunenberg N, Huang Y, Grove D, Prigmore B, Kee JJ, Benkeser D, Hural J, Innes C, Lazarus E, Meintjes G, Naicker N, Kalonji D, Nchabeleng M, Sebe M, Singh N, Kotze P, Kassim S, Dubula T, Naicker V, Brumskine W, Ncayiya CN, Ward AM, Garrett N, Kistnasami G, Gaffoor Z, Selepe P, Makhoba PB, Mathebula MP, Mda P, Adonis T, Mapetla KS, Modibedi B, Philip T, Kobane G, Bentley C, Ramirez S, Takuva S, Jones M, Sikhosana M, Atujuna M, Andrasik M, Hejazi NS, Puren A, Wiesner L, Phogat S, Diaz Granados C, Koutsoukos M, Van Der Meeren O, Barnett SW, Kanesa-Thasan N, Kublin JG, McElrath MJ, Gilbert PB, Janes H, Corey L; HVTN 702 Study Team.","N Engl J Med. 2021 Mar 25;384(12):1089-1100. doi: 10.1056/NEJMoa2031499.","Gray GE","N Engl J Med","2021","2021/03/24","PMC7888373","","10.1056/NEJMoa2031499"
"33090877","Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials","Mehrotra DV, Janes HE, Fleming TR, Annunziato PW, Neuzil KM, Carpp LN, Benkeser D, Brown ER, Carone M, Cho I, Donnell D, Fay MP, Fong Y, Han S, Hirsch I, Huang Y, Huang Y, Hyrien O, Juraska M, Luedtke A, Nason M, Vandebosch A, Zhou H, Cohen MS, Corey L, Hartzel J, Follmann D, Gilbert PB.","Ann Intern Med. 2021 Feb;174(2):221-228. doi: 10.7326/M20-6169. Epub 2020 Oct 22.","Mehrotra DV","Ann Intern Med","2021","2020/10/22","PMC7596738","","10.7326/M20-6169"
"35758878","Analysis of the HIV Vaccine Trials Network 702 Phase 2b-3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk","Moodie Z, Dintwe O, Sawant S, Grove D, Huang Y, Janes H, Heptinstall J, Omar FL, Cohen K, De Rosa SC, Zhang L, Yates NL, Sarzotti-Kelsoe M, Seaton KE, Laher F, Bekker LG, Malahleha M, Innes C, Kassim S, Naicker N, Govender V, Sebe M, Singh N, Kotze P, Lazarus E, Nchabeleng M, Ward AM, Brumskine W, Dubula T, Randhawa AK, Grunenberg N, Hural J, Kee JJ, Benkeser D, Jin Y, Carpp LN, Allen M, D'Souza P, Tartaglia J, DiazGranados CA, Koutsoukos M, Gilbert PB, Kublin JG, Corey L, Andersen-Nissen E, Gray GE, Tomaras GD, McElrath MJ.","J Infect Dis. 2022 Aug 24;226(2):246-257. doi: 10.1093/infdis/jiac260.","Moodie Z","J Infect Dis","2022","2022/06/27","PMC9890908","","10.1093/infdis/jiac260"
"27662407","Modeling HIV vaccine trials of the future","Gilbert PB, Huang Y, Janes HE.","Curr Opin HIV AIDS. 2016 Nov;11(6):620-627. doi: 10.1097/COH.0000000000000314.","Gilbert PB","Curr Opin HIV AIDS","2016","2016/09/24","PMC5077275","NIHMS823977","10.1097/COH.0000000000000314"
"35493113","COVID-19 Vaccines and SARS-CoV-2 Transmission in the Era of New Variants: A Review and Perspective","Marcelin JR, Pettifor A, Janes H, Brown ER, Kublin JG, Stephenson KE.","Open Forum Infect Dis. 2022 Mar 10;9(5):ofac124. doi: 10.1093/ofid/ofac124. eCollection 2022 May.","Marcelin JR","Open Forum Infect Dis","2022","2022/05/02","PMC8992234","","10.1093/ofid/ofac124"
"33880481","Evaluating Vaccine Efficacy Against SARS-CoV-2 Infection","Lin DY, Gu Y, Zeng D, Janes HE, Gilbert PB.","medRxiv. 2021 Apr 17:2021.04.16.21255614. doi: 10.1101/2021.04.16.21255614. Preprint.","Lin DY","medRxiv","2021","2021/04/21","PMC8057249","","10.1101/2021.04.16.21255614"
"28129522","Reply to A.J. Vickers et al","Kerr KF, Brown M, Janes H.","J Clin Oncol. 2017 Feb;35(4):473-475. doi: 10.1200/JCO.2016.70.4288. Epub 2016 Nov 14.","Kerr KF","J Clin Oncol","2017","2017/01/28","","","10.1200/JCO.2016.70.4288"
"26827165","Selection of HIV vaccine candidates for concurrent testing in an efficacy trial","Huang Y, DiazGranados C, Janes H, Huang Y, deCamp AC, Metch B, Grant S, Sanchez B, Phogat S, Koutsoukos M, Kanesa-Thasan N, Bourguignon P, Collard A, Buchbinder S, Tomaras GD, McElrath J, Gray G, Kublin JG, Corey L, Gilbert PB.","Curr Opin Virol. 2016 Apr;17:57-65. doi: 10.1016/j.coviro.2016.01.007. Epub 2016 Jan 29.","Huang Y","Curr Opin Virol","2016","2016/02/01","PMC4902743","NIHMS756136","10.1016/j.coviro.2016.01.007"
"23872613","New clinical trial designs for HIV vaccine evaluation","Moodie Z, Janes H, Huang Y.","Curr Opin HIV AIDS. 2013 Sep;8(5):437-42. doi: 10.1097/COH.0b013e328363d46a.","Moodie Z","Curr Opin HIV AIDS","2013","2013/07/23","PMC3872029","NIHMS533773","10.1097/COH.0b013e328363d46a"
"29732896","Weighing the Evidence of Efficacy of Oral PrEP for HIV Prevention in Women in Southern Africa","Janes H, Corey L, Ramjee G, Carpp LN, Lombard C, Cohen MS, Gilbert PB, Gray GE.","AIDS Res Hum Retroviruses. 2018 Aug;34(8):645-656. doi: 10.1089/AID.2018.0031. Epub 2018 Jun 19.","Janes H","AIDS Res Hum Retroviruses","2018","2018/05/08","PMC6080090","","10.1089/AID.2018.0031"
"31078451","Taking stock of the present and looking ahead: envisioning challenges in the design of future HIV prevention efficacy trials","Janes H, Donnell D, Gilbert PB, Brown ER, Nason M.","Lancet HIV. 2019 Jul;6(7):e475-e482. doi: 10.1016/S2352-3018(19)30133-X. Epub 2019 May 8.","Janes H","Lancet HIV","2019","2019/05/13","PMC6612578","NIHMS1529465","10.1016/S2352-3018(19)30133-X"
"23624212","Letter to the editor","Janes H.","Biostatistics. 2013 Sep;14(4):807-8. doi: 10.1093/biostatistics/kxt013. Epub 2013 Apr 26.","Janes H","Biostatistics","2013","2013/04/30","PMC3841383","","10.1093/biostatistics/kxt013"
"21407270","Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration","Janssens AC, Ioannidis JP, Bedrosian S, Boffetta P, Dolan SM, Dowling N, Fortier I, Freedman AN, Grimshaw JM, Gulcher J, Gwinn M, Hlatky MA, Janes H, Kraft P, Melillo S, O'Donnell CJ, Pencina MJ, Ransohoff D, Schully SD, Seminara D, Winn DM, Wright CF, van Duijn CM, Little J, Khoury MJ.","Eur J Hum Genet. 2011 May;19(5):18 p preceding 494. doi: 10.1038/ejhg.2011.27.","Janssens AC","Eur J Hum Genet","2011","2011/03/17","PMC3083630","","10.1038/ejhg.2011.27"
"24240655","Net reclassification indices for evaluating risk prediction instruments: a critical review","Kerr KF, Wang Z, Janes H, McClelland RL, Psaty BM, Pepe MS.","Epidemiology. 2014 Jan;25(1):114-21. doi: 10.1097/EDE.0000000000000018.","Kerr KF","Epidemiology","2014","2013/11/19","PMC3918180","NIHMS541797","10.1097/EDE.0000000000000018"
"20203259","On quantifying the magnitude of confounding","Janes H, Dominici F, Zeger S.","Biostatistics. 2010 Jul;11(3):572-82. doi: 10.1093/biostatistics/kxq007. Epub 2010 Mar 4.","Janes H","Biostatistics","2010","2010/03/06","PMC2883302","","10.1093/biostatistics/kxq007"
"37392020","Perspectives on Design Approaches for HIV Prevention Efficacy Trials","Prudden HJ, Tatoud R, Janes H, Wallace S, Miller V, Bekker LG, Donnell D.","AIDS Res Hum Retroviruses. 2023 Jun 30. doi: 10.1089/AID.2022.0150. Online ahead of print.","Prudden HJ","AIDS Res Hum Retroviruses","2023","2023/07/01","","","10.1089/AID.2022.0150"
"21502867","Strengthening the reporting of Genetic Risk Prediction Studies: the GRIPS statement","Janssens AC, Ioannidis JP, van Duijn CM, Little J, Khoury MJ; GRIPS Group.","Genet Med. 2011 May;13(5):453-6. doi: 10.1097/GIM.0b013e318212fa82.","Janssens AC","Genet Med","2011","2011/04/20","","","10.1097/GIM.0b013e318212fa82"
"34696352","Mathematical Modeling of Vaccines That Prevent SARS-CoV-2 Transmission","Swan DA, Goyal A, Bracis C, Moore M, Krantz E, Brown E, Cardozo-Ojeda F, Reeves DB, Gao F, Gilbert PB, Corey L, Cohen MS, Janes H, Dimitrov D, Schiffer JT.","Viruses. 2021 Sep 24;13(10):1921. doi: 10.3390/v13101921.","Swan DA","Viruses","2021","2021/10/26","PMC8539635","","10.3390/v13101921"
"34532060","RV144 vaccine imprinting constrained HIV-1 evolution following breakthrough infection","Lewitus E, Sanders-Buell E, Bose M, O'Sullivan AM, Poltavee K, Li Y, Bai H, Mdluli T, Donofrio G, Slike B, Zhao H, Wong K, Chen L, Miller S, Lee J, Ahani B, Lepore S, Muhammad S, Grande R, Tran U, Dussupt V, Mendez-Rivera L, Nitayaphan S, Kaewkungwal J, Pitisuttithum P, Rerks-Ngarm S, O'Connell RJ, Janes H, Gilbert PB, Gramzinski R, Vasan S, Robb ML, Michael NL, Krebs SJ, Herbeck JT, Edlefsen PT, Mullins JI, Kim JH, Tovanabutra S, Rolland M.","Virus Evol. 2021 Jul 9;7(2):veab057. doi: 10.1093/ve/veab057. eCollection 2021.","Lewitus E","Virus Evol","2021","2021/09/17","PMC8438874","","10.1093/ve/veab057"
"35503767","Mycobacterium tuberculosis infection, immune activation, and risk of HIV acquisition","Bender Ignacio RA, Long J, Saha A, Nguyen FK, Joudeh L, Valinetz E, Mendelsohn SC, Scriba TJ, Hatherill M, Janes H, Churchyard G, Buchbinder S, Duerr A, Shah JA, Hawn TR.","PLoS One. 2022 May 3;17(5):e0267729. doi: 10.1371/journal.pone.0267729. eCollection 2022.","Bender Ignacio RA","PLoS One","2022","2022/05/03","PMC9064099","","10.1371/journal.pone.0267729"
"34260716","Evaluating Vaccine Efficacy Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection","Lin DY, Gu Y, Zeng D, Janes HE, Gilbert PB.","Clin Infect Dis. 2022 Feb 11;74(3):544-552. doi: 10.1093/cid/ciab630.","Lin DY","Clin Infect Dis","2022","2021/07/14","PMC8406869","","10.1093/cid/ciab630"
"15105181","Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker","Pepe MS, Janes H, Longton G, Leisenring W, Newcomb P.","Am J Epidemiol. 2004 May 1;159(9):882-90. doi: 10.1093/aje/kwh101.","Pepe MS","Am J Epidemiol","2004","2004/04/24","","","10.1093/aje/kwh101"
"20046933","Accommodating Covariates in ROC Analysis","Janes H, Longton G, Pepe M.","Stata J. 2009 Jan 1;9(1):17-39.","Janes H","Stata J","2009","2010/01/05","PMC2758790","NIHMS90149",""
"37330602","Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration","Follmann D, O'Brien MP, Fintzi J, Fay MP, Montefiori D, Mateja A, Herman GA, Hooper AT, Turner KC, Chan KC, Forleo-Neto E, Isa F, Baden LR, El Sahly HM, Janes H, Doria-Rose N, Miller J, Zhou H, Dang W, Benkeser D, Fong Y, Gilbert PB, Marovich M, Cohen MS.","Nat Commun. 2023 Jun 17;14(1):3605. doi: 10.1038/s41467-023-39292-w.","Follmann D","Nat Commun","2023","2023/06/17","PMC10276829","","10.1038/s41467-023-39292-w"
"36899062","Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine","Benkeser D, Fong Y, Janes HE, Kelly EJ, Hirsch I, Sproule S, Stanley AM, Maaske J, Villafana T, Houchens CR, Martins K, Jayashankar L, Castellino F, Ayala V, Petropoulos CJ, Leith A, Haugaard D, Webb B, Lu Y, Yu C, Borate B, van der Laan LWP, Hejazi NS, Carpp LN, Randhawa AK, Andrasik MP, Kublin JG, Isaacs MB, Makhene M, Tong T, Robb ML, Corey L, Neuzil KM, Follmann D, Hoffman C, Falsey AR, Sobieszczyk M, Koup RA, Donis RO, Gilbert PB; AstraZeneca AZD1222 Clinical Study Group; Immune Assays Team; United States Government (USG)/CoVPN Biostatistics Team.","NPJ Vaccines. 2023 Mar 11;8(1):36. doi: 10.1038/s41541-023-00630-0.","Benkeser D","NPJ Vaccines","2023","2023/03/10","PMC10005913","","10.1038/s41541-023-00630-0"
"28819997","Comparisons of cancer staging systems should be based on overall performance in the population","Kerr KF, LeBlanc M, Janes H.","Clin Trials. 2017 Dec;14(6):659-660. doi: 10.1177/1740774517722141. Epub 2017 Aug 18.","Kerr KF","Clin Trials","2017","2017/08/19","PMC5714691","NIHMS890326","10.1177/1740774517722141"
"18612128","Gauging the performance of SNPs, biomarkers, and clinical factors for predicting risk of breast cancer","Pepe MS, Janes HE.","J Natl Cancer Inst. 2008 Jul 16;100(14):978-9. doi: 10.1093/jnci/djn215. Epub 2008 Jul 8.","Pepe MS","J Natl Cancer Inst","2008","2008/07/10","PMC3132154","NIHMS287193","10.1093/jnci/djn215"
"36883907","Retrospective, Observational Studies for Estimating Vaccine Effects on the Secondary Attack Rate of SARS-CoV-2","Bannick MS, Gao F, Brown ER, Janes HE.","Am J Epidemiol. 2023 Jun 2;192(6):1016-1028. doi: 10.1093/aje/kwad046.","Bannick MS","Am J Epidemiol","2023","2023/03/08","","","10.1093/aje/kwad046"
"35675078","Durability of Protection Against Symptomatic COVID-19 Among Participants of the mRNA-1273 SARS-CoV-2 Vaccine Trial","Lin DY, Baden LR, El Sahly HM, Essink B, Neuzil KM, Corey L, Miller J; COVE Study Group.","JAMA Netw Open. 2022 Jun 1;5(6):e2215984. doi: 10.1001/jamanetworkopen.2022.15984.","Lin DY","JAMA Netw Open","2022","2022/06/08","PMC9178430","","10.1001/jamanetworkopen.2022.15984"
"30649998","Assessing the Clinical Impact of Risk Models for Opting Out of Treatment","Kerr KF, Brown MD, Marsh TL, Janes H.","Med Decis Making. 2019 Feb;39(2):86-90. doi: 10.1177/0272989X18819479. Epub 2019 Jan 16.","Kerr KF","Med Decis Making","2019","2019/01/17","PMC6374190","NIHMS1514491","10.1177/0272989X18819479"
"34790985","Could widespread use of antiviral treatment curb the COVID-19 pandemic? A modeling study","Matrajt L, Brown ER, Cohen MS, Dimitrov D, Janes H.","medRxiv. 2022 Apr 4:2021.11.10.21266139. doi: 10.1101/2021.11.10.21266139. Preprint.","Matrajt L","medRxiv","2022","2021/11/18","PMC8597888","","10.1101/2021.11.10.21266139"
"33469590","Optimizing vaccine allocation for COVID-19 vaccines: potential role of single-dose vaccination","Matrajt L, Eaton J, Leung T, Dimitrov D, Schiffer JT, Swan DA, Janes H.","medRxiv. 2021 Apr 15:2020.12.31.20249099. doi: 10.1101/2020.12.31.20249099. Preprint.","Matrajt L","medRxiv","2021","2021/01/20","PMC7814836","","10.1101/2020.12.31.20249099"
"35945513","Could widespread use of antiviral treatment curb the COVID-19 pandemic? A modeling study","Matrajt L, Brown ER, Cohen MS, Dimitrov D, Janes H.","BMC Infect Dis. 2022 Aug 9;22(1):683. doi: 10.1186/s12879-022-07639-1.","Matrajt L","BMC Infect Dis","2022","2022/08/09","PMC9361252","","10.1186/s12879-022-07639-1"
"36106642","Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6 months","Sobieszczyk ME, Maaske J, Falsey AR, Sproule S, Robb ML, Frenck RW Jr, Tieu HV, Mayer KH, Corey L, Neuzil KM, Tong T, Brewinski Isaacs M, Janes H, Bansal H, Edwards LM, Green JA, Kelly EJ, Shoemaker K, Takas T, White T, Bhuyan P, Villafana T, Hirsch AI; AstraZeneca AZD1222 Clinical Study Group.","J Clin Invest. 2022 Sep 15;132(18):e160565. doi: 10.1172/JCI160565.","Sobieszczyk ME","J Clin Invest","2022","2022/09/15","PMC9479753","","10.1172/JCI160565"
"31104561","The Importance of Uncertainty and Opt-In v. Opt-Out: Best Practices for Decision Curve Analysis","Kerr KF, Marsh TL, Janes H.","Med Decis Making. 2019 Jul;39(5):491-492. doi: 10.1177/0272989X19849436. Epub 2019 May 20.","Kerr KF","Med Decis Making","2019","2019/05/21","PMC6786944","NIHMS1527393","10.1177/0272989X19849436"
"34103510","Optimizing vaccine allocation for COVID-19 vaccines shows the potential role of single-dose vaccination","Matrajt L, Eaton J, Leung T, Dimitrov D, Schiffer JT, Swan DA, Janes H.","Nat Commun. 2021 Jun 8;12(1):3449. doi: 10.1038/s41467-021-23761-1.","Matrajt L","Nat Commun","2021","2021/06/09","PMC8187351","","10.1038/s41467-021-23761-1"
"31589165","Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk","Neidich SD, Fong Y, Li SS, Geraghty DE, Williamson BD, Young WC, Goodman D, Seaton KE, Shen X, Sawant S, Zhang L, deCamp AC, Blette BS, Shao M, Yates NL, Feely F, Pyo CW, Ferrari G; HVTN 505 Team; Frank I, Karuna ST, Swann EM, Mascola JR, Graham BS, Hammer SM, Sobieszczyk ME, Corey L, Janes HE, McElrath MJ, Gottardo R, Gilbert PB, Tomaras GD.","J Clin Invest. 2019 Nov 1;129(11):4838-4849. doi: 10.1172/JCI126391.","Neidich SD","J Clin Invest","2019","2019/10/08","PMC6819135","","10.1172/JCI126391"
"31732971","Statistical inference for net benefit measures in biomarker validation studies","Marsh TL, Janes H, Pepe MS.","Biometrics. 2020 Sep;76(3):843-852. doi: 10.1111/biom.13190. Epub 2019 Nov 28.","Marsh TL","Biometrics","2020","2019/11/17","PMC7228830","NIHMS1561755","10.1111/biom.13190"
"34492117","Discussion on ""Estimating vaccine efficacy over time after a randomized study is unblinded"" by Anastasios A. Tsiatis and Marie Davidian","Janes H, Gao F, Luedtke A.","Biometrics. 2022 Sep;78(3):841-843. doi: 10.1111/biom.13542. Epub 2021 Sep 7.","Janes H","Biometrics","2022","2021/09/07","PMC8653041","","10.1111/biom.13542"
"24889663","Combining biomarkers to optimize patient treatment recommendations","Kang C, Janes H, Huang Y.","Biometrics. 2014 Sep;70(3):695-707. doi: 10.1111/biom.12191. Epub 2014 May 30.","Kang C","Biometrics","2014","2014/06/04","PMC4248022","NIHMS636410","10.1111/biom.12191"
"25454855","Use of placebos in Phase 1 preventive HIV vaccine clinical trials","Huang Y, Karuna ST, Janes H, Frahm N, Nason M, Edlefsen PT, Kublin JG, Corey L, McElrath MJ, Gilbert PB.","Vaccine. 2015 Feb 4;33(6):749-52. doi: 10.1016/j.vaccine.2014.10.017. Epub 2014 Oct 23.","Huang Y","Vaccine","2015","2014/12/03","PMC4554766","NIHMS715614","10.1016/j.vaccine.2014.10.017"
"30623732","Methods for comparing durability of immune responses between vaccine regimens in early-phase trials","Westling T, Juraska M, Seaton KE, Tomaras GD, Gilbert PB, Janes H.","Stat Methods Med Res. 2020 Jan;29(1):78-93. doi: 10.1177/0962280218820881. Epub 2019 Jan 9.","Westling T","Stat Methods Med Res","2020","2019/01/10","PMC6682462","NIHMS1043746","10.1177/0962280218820881"
"37018240","Sexually transmitted infections amongst men who have sex with men (MSM) in South Africa","Mashingaidze R, Moodie Z, Allen M, Bekker LG, Grove D, Grunenberg N, Huang Y, Janes HE, Lazarus EM, Malahleha M, Nchabeleng M, Laher F.","PLOS Glob Public Health. 2023 Apr 5;3(4):e0001782. doi: 10.1371/journal.pgph.0001782. eCollection 2023.","Mashingaidze R","PLOS Glob Public Health","2023","2023/04/05","PMC10075439","","10.1371/journal.pgph.0001782"
"36689221","Rapid Development of an Integrated Network Infrastructure to Conduct Phase 3 COVID-19 Vaccine Trials","Mena Lora AJ, Long JE, Huang Y, Baden LR, El Sahly HM, Follmann D, Goepfert P, Gray G, Grinsztejn B, Kotloff K, Rouphael N, Sobieszczyk M, Walsh SR, Andriesen J, Shah KA, Zhang Y, Gilbert P, Janes H, Gay CL, Falsey AR, Tripp RL, Gorman RL, Tong T, Marovich M, Neuzil K, Corey L, Kublin JG; COVID-19 Prevention Network.","JAMA Netw Open. 2023 Jan 3;6(1):e2251974. doi: 10.1001/jamanetworkopen.2022.51974.","Mena Lora AJ","JAMA Netw Open","2023","2023/01/23","","","10.1001/jamanetworkopen.2022.51974"
"26109106","The Fundamental Difficulty With Evaluating the Accuracy of Biomarkers for Guiding Treatment","Janes H, Pepe MS, McShane LM, Sargent DJ, Heagerty PJ.","J Natl Cancer Inst. 2015 Jun 24;107(8):djv157. doi: 10.1093/jnci/djv157. Print 2015 Aug.","Janes H","J Natl Cancer Inst","2015","2015/06/26","PMC4609557","","10.1093/jnci/djv157"
"28960244","Case-only approach to identifying markers predicting treatment effects on the relative risk scale","Dai JY, Liang CJ, LeBlanc M, Prentice RL, Janes H.","Biometrics. 2018 Jun;74(2):753-763. doi: 10.1111/biom.12789. Epub 2017 Sep 28.","Dai JY","Biometrics","2018","2017/09/30","PMC5874156","NIHMS907053","10.1111/biom.12789"
"29156498","First things first: risk model performance metrics should reflect the clinical application","Kerr KF, Janes H.","Stat Med. 2017 Dec 10;36(28):4503-4508. doi: 10.1002/sim.7341.","Kerr KF","Stat Med","2017","2017/11/21","PMC5726302","NIHMS874570","10.1002/sim.7341"
"34307733","Quantifying the Impact of Lifting Community Nonpharmaceutical Interventions for COVID-19 During Vaccination Rollout in the United States","Matrajt L, Janes H, Schiffer JT, Dimitrov D.","Open Forum Infect Dis. 2021 Jun 30;8(7):ofab341. doi: 10.1093/ofid/ofab341. eCollection 2021 Jul.","Matrajt L","Open Forum Infect Dis","2021","2021/07/26","PMC8294674","","10.1093/ofid/ofab341"
"29444553","Evaluation of biomarkers for treatment selection using individual participant data from multiple clinical trials","Kang C, Janes H, Tajik P, Groen H, Mol B, Koopmans C, Broekhuijsen K, Zwertbroek E, van Pampus M, Franssen M.","Stat Med. 2018 Apr 30;37(9):1439-1453. doi: 10.1002/sim.7608. Epub 2018 Feb 14.","Kang C","Stat Med","2018","2018/02/15","PMC5889758","NIHMS932974","10.1002/sim.7608"
"24681599","Net risk reclassification p values: valid or misleading?","Pepe MS, Janes H, Li CI.","J Natl Cancer Inst. 2014 Apr;106(4):dju041. doi: 10.1093/jnci/dju041. Epub 2014 Mar 28.","Pepe MS","J Natl Cancer Inst","2014","2014/04/01","PMC3982889","","10.1093/jnci/dju041"
"36929319","Risk Factors Associated with HIV Acquisition in Males Participating in HIV Vaccine Efficacy Trials in South Africa","Malahleha M, Laher F, Dilraj A, Smith P, Gray GE, Grove D, Odhiambo JA, Andrasik MP, Grunenberg NA, Moodie Z, Huang Y, Borate BR, Gillespie KM, Allen M, Atujuna M, Singh N, Kalonji D, Meintjes G, Kotze P, Bekker LG, Janes H.","AIDS Behav. 2023 Sep;27(9):3027-3037. doi: 10.1007/s10461-023-04025-z. Epub 2023 Mar 16.","Malahleha M","AIDS Behav","2023","2023/03/17","PMC10386918","","10.1007/s10461-023-04025-z"
"27037797","Power/sample size calculations for assessing correlates of risk in clinical efficacy trials","Gilbert PB, Janes HE, Huang Y.","Stat Med. 2016 Sep 20;35(21):3745-59. doi: 10.1002/sim.6952. Epub 2016 Mar 31.","Gilbert PB","Stat Med","2016","2016/04/03","PMC4965346","NIHMS773751","10.1002/sim.6952"
"37075127","Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial","Benkeser D, Montefiori DC, McDermott AB, Fong Y, Janes HE, Deng W, Zhou H, Houchens CR, Martins K, Jayashankar L, Castellino F, Flach B, Lin BC, O'Connell S, McDanal C, Eaton A, Sarzotti-Kelsoe M, Lu Y, Yu C, Borate B, van der Laan LWP, Hejazi NS, Kenny A, Carone M, Williamson BD, Garver J, Altonen E, Rudge T, Huynh C, Miller J, El Sahly HM, Baden LR, Frey S, Malkin E, Spector SA, Andrasik MP, Kublin JG, Corey L, Neuzil KM, Carpp LN, Pajon R, Follmann D, Donis RO, Koup RA, Gilbert PB; Immune Assays; Moderna Inc.; Coronavirus Vaccine Prevention Network (CoVPN)/Coronavirus Efficacy (COVE); United States Government (USG)/CoVPN Biostatistics Teams.","Sci Transl Med. 2023 Apr 19;15(692):eade9078. doi: 10.1126/scitranslmed.ade9078. Epub 2023 Apr 19.","Benkeser D","Sci Transl Med","2023","2023/04/19","PMC10243212","NIHMS1899084","10.1126/scitranslmed.ade9078"
"21571811","Commentary: Reporting standards are needed for evaluations of risk reclassification","Pepe MS, Janes H.","Int J Epidemiol. 2011 Aug;40(4):1106-8. doi: 10.1093/ije/dyr083. Epub 2011 May 13.","Pepe MS","Int J Epidemiol","2011","2011/05/17","PMC3156371","","10.1093/ije/dyr083"
"32747654","Impact of vaccine type on HIV-1 vaccine elicited antibody durability and B cell gene signature","Palli R, Seaton KE, Piepenbrink MS, Hural J, Goepfert PA, Laher F, Buchbinder SP, Churchyard G, Gray GE, Robinson HL, Huang Y, Janes H, Kobie JJ, Keefer MC, Tomaras GD, Thakar J.","Sci Rep. 2020 Aug 3;10(1):13031. doi: 10.1038/s41598-020-69007-w.","Palli R","Sci Rep","2020","2020/08/05","PMC7398916","","10.1038/s41598-020-69007-w"
"22299708","Assessing treatment-selection markers using a potential outcomes framework","Huang Y, Gilbert PB, Janes H.","Biometrics. 2012 Sep;68(3):687-96. doi: 10.1111/j.1541-0420.2011.01722.x. Epub 2012 Feb 2.","Huang Y","Biometrics","2012","2012/02/04","PMC3417090","NIHMS373252","10.1111/j.1541-0420.2011.01722.x"
"20161343","Estimation and Comparison of Receiver Operating Characteristic Curves","Pepe M, Longton G, Janes H.","Stata J. 2009 Mar 1;9(1):1.","Pepe M","Stata J","2009","2010/02/18","PMC2774909","NIHMS90148",""
"26112650","Designing a study to evaluate the benefit of a biomarker for selecting patient treatment","Janes H, Brown MD, Pepe MS.","Stat Med. 2015 Nov 30;34(27):3503-15. doi: 10.1002/sim.6564. Epub 2015 Jun 25.","Janes H","Stat Med","2015","2015/06/27","PMC4626364","NIHMS701535","10.1002/sim.6564"
"33336213","Assessing Durability of Vaccine Effect Following Blinded Crossover in COVID-19 Vaccine Efficacy Trials","Follmann D, Fintzi J, Fay MP, Janes HE, Baden L, Sahly HE, Fleming TR, Mehrotra DV, Carpp LN, Juraska M, Benkeser D, Donnell D, Fong Y, Han S, Hirsch I, Huang Y, Huang Y, Hyrien O, Luedtke A, Carone M, Nason M, Vandebosch A, Zhou H, Cho I, Gabriel E, Kublin JG, Cohen MS, Corey L, Gilbert PB, Neuzil KM.","medRxiv. 2020 Dec 14:2020.12.14.20248137. doi: 10.1101/2020.12.14.20248137. Preprint.","Follmann D","medRxiv","2020","2020/12/18","PMC7745130","","10.1101/2020.12.14.20248137"
"24099601","Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine","Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, Grove D, Koblin BA, Buchbinder SP, Keefer MC, Tomaras GD, Frahm N, Hural J, Anude C, Graham BS, Enama ME, Adams E, DeJesus E, Novak RM, Frank I, Bentley C, Ramirez S, Fu R, Koup RA, Mascola JR, Nabel GJ, Montefiori DC, Kublin J, McElrath MJ, Corey L, Gilbert PB; HVTN 505 Study Team.","N Engl J Med. 2013 Nov 28;369(22):2083-92. doi: 10.1056/NEJMoa1310566. Epub 2013 Oct 7.","Hammer SM","N Engl J Med","2013","2013/10/09","PMC4030634","NIHMS552686","10.1056/NEJMoa1310566"
"22475592","Immune-correlates analysis of an HIV-1 vaccine efficacy trial","Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, Liao HX, DeVico AL, Lewis GK, Williams C, Pinter A, Fong Y, Janes H, DeCamp A, Huang Y, Rao M, Billings E, Karasavvas N, Robb ML, Ngauy V, de Souza MS, Paris R, Ferrari G, Bailer RT, Soderberg KA, Andrews C, Berman PW, Frahm N, De Rosa SC, Alpert MD, Yates NL, Shen X, Koup RA, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Rerks-Ngarm S, Michael NL, Kim JH.","N Engl J Med. 2012 Apr 5;366(14):1275-86. doi: 10.1056/NEJMoa1113425.","Haynes BF","N Engl J Med","2012","2012/04/06","PMC3371689","NIHMS371846","10.1056/NEJMoa1113425"
"26343159","Identifying post-menopausal women at elevated risk for epithelial ovarian cancer","Urban N, Hawley S, Janes H, Karlan BY, Berg CD, Drescher CW, Manson JE, Palomares MR, Daly MB, Wactawski-Wende J, O'Sullivan MJ, Thorpe J, Robinson RD, Lane D, Li CI, Anderson GL.","Gynecol Oncol. 2015 Nov;139(2):253-60. doi: 10.1016/j.ygyno.2015.08.024. Epub 2015 Sep 3.","Urban N","Gynecol Oncol","2015","2015/09/08","PMC4664187","NIHMS732236","10.1016/j.ygyno.2015.08.024"
"23878319","Vaccine-induced gag-specific T cells are associated with reduced viremia after HIV-1 infection","Janes H, Friedrich DP, Krambrink A, Smith RJ, Kallas EG, Horton H, Casimiro DR, Carrington M, Geraghty DE, Gilbert PB, McElrath MJ, Frahm N.","J Infect Dis. 2013 Oct 15;208(8):1231-9. doi: 10.1093/infdis/jit322. Epub 2013 Jul 21.","Janes H","J Infect Dis","2013","2013/07/24","PMC3778967","","10.1093/infdis/jit322"
"21434890","Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration","Janssens AC, Ioannidis JP, Bedrosian S, Boffetta P, Dolan SM, Dowling N, Fortier I, Freedman AN, Grimshaw JM, Gulcher J, Gwinn M, Hlatky MA, Janes H, Kraft P, Melillo S, O'Donnell CJ, Pencina MJ, Ransohoff D, Schully SD, Seminara D, Winn DM, Wright CF, van Duijn CM, Little J, Khoury MJ.","Eur J Clin Invest. 2011 Sep;41(9):1010-35. doi: 10.1111/j.1365-2362.2011.02493.x. Epub 2011 Mar 15.","Janssens AC","Eur J Clin Invest","2011","2011/03/26","","","10.1111/j.1365-2362.2011.02493.x"
"35785530","Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial","Follmann D, Janes HE, Buhule OD, Zhou H, Girard B, Marks K, Kotloff K, Desjardins M, Corey L, Neuzil KM, Miller JM, El Sahly HM, Baden LR.","Ann Intern Med. 2022 Sep;175(9):1258-1265. doi: 10.7326/M22-1300. Epub 2022 Jul 5.","Follmann D","Ann Intern Med","2022","2022/07/05","PMC9258784","","10.7326/M22-1300"
"26322580","HIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders","Janes H, Herbeck JT, Tovanabutra S, Thomas R, Frahm N, Duerr A, Hural J, Corey L, Self SG, Buchbinder SP, McElrath MJ, O'Connell RJ, Paris RM, Rerks-Ngarm S, Nitayaphan S, Pitisuttihum P, Kaewkungwal J, Robb ML, Michael NL, Mullins JI, Kim JH, Gilbert PB, Rolland M.","Nat Med. 2015 Oct;21(10):1139-41. doi: 10.1038/nm.3932. Epub 2015 Aug 31.","Janes H","Nat Med","2015","2015/09/01","PMC4598284","NIHMS711050","10.1038/nm.3932"
"33844575","A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is Vaccinated","Follmann D, Fintzi J, Fay MP, Janes HE, Baden LR, El Sahly HM, Fleming TR, Mehrotra DV, Carpp LN, Juraska M, Benkeser D, Donnell D, Fong Y, Han S, Hirsch I, Huang Y, Huang Y, Hyrien O, Luedtke A, Carone M, Nason M, Vandebosch A, Zhou H, Cho I, Gabriel E, Kublin JG, Cohen MS, Corey L, Gilbert PB, Neuzil KM.","Ann Intern Med. 2021 Aug;174(8):1118-1125. doi: 10.7326/M20-8149. Epub 2021 Apr 13.","Follmann D","Ann Intern Med","2021","2021/04/12","PMC8099035","","10.7326/M20-8149"
"36938334","Designing HIV Vaccine Efficacy Trials in the Context of Highly Effective Non-vaccine Prevention Modalities","Janes H, Zhu Y, Brown ER.","Stat Biosci. 2020 Dec;12(3):468-494. doi: 10.1007/s12561-020-09292-1. Epub 2020 Oct 22.","Janes H","Stat Biosci","2020","2023/03/20","PMC10022814","NIHMS1834234","10.1007/s12561-020-09292-1"
"21424820","Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration","Janssens AC, Ioannidis JP, Bedrosian S, Boffetta P, Dolan SM, Dowling N, Fortier I, Freedman AN, Grimshaw JM, Gulcher J, Gwinn M, Hlatky MA, Janes H, Kraft P, Melillo S, O'Donnell CJ, Pencina MJ, Ransohoff D, Schully SD, Seminara D, Winn DM, Wright CF, van Duijn CM, Little J, Khoury MJ.","Eur J Epidemiol. 2011 Apr;26(4):313-37. doi: 10.1007/s10654-011-9551-z.","Janssens AC","Eur J Epidemiol","2011","2011/03/23","PMC3088812","NIHMS285488","10.1007/s10654-011-9551-z"
"26510957","STARD 2015: An Updated List of Essential Items for Reporting Diagnostic Accuracy Studies","Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, Lijmer JG, Moher D, Rennie D, de Vet HC, Kressel HY, Rifai N, Golub RM, Altman DG, Hooft L, Korevaar DA, Cohen JF; STARD Group.","Clin Chem. 2015 Dec;61(12):1446-52. doi: 10.1373/clinchem.2015.246280. Epub 2015 Oct 28.","Bossuyt PM","Clin Chem","2015","2015/10/30","","","10.1373/clinchem.2015.246280"
"25105367","FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial","Li SS, Gilbert PB, Tomaras GD, Kijak G, Ferrari G, Thomas R, Pyo CW, Zolla-Pazner S, Montefiori D, Liao HX, Nabel G, Pinter A, Evans DT, Gottardo R, Dai JY, Janes H, Morris D, Fong Y, Edlefsen PT, Li F, Frahm N, Alpert MD, Prentice H, Rerks-Ngarm S, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Robb ML, O'Connell RJ, Haynes BF, Michael NL, Kim JH, McElrath MJ, Geraghty DE.","J Clin Invest. 2014 Sep;124(9):3879-90. doi: 10.1172/JCI75539. Epub 2014 Aug 8.","Li SS","J Clin Invest","2014","2014/08/09","PMC4151214","","10.1172/JCI75539"
"24029738","Have the explosive HIV epidemics in sub-Saharan Africa been driven by higher community viral load?","Abu-Raddad LJ, Barnabas RV, Janes H, Weiss HA, Kublin JG, Longini IM Jr, Wasserheit JN.","AIDS. 2013 Sep 24;27(15):2494-6. doi: 10.1097/01.aids.0000432463.23508.a2.","Abu-Raddad LJ","AIDS","2013","2013/09/14","","","10.1097/01.aids.0000432463.23508.a2"
"32949147","Efficient nonparametric inference on the effects of stochastic interventions under two-phase sampling, with applications to vaccine efficacy trials","Hejazi NS, van der Laan MJ, Janes HE, Gilbert PB, Benkeser DC.","Biometrics. 2021 Dec;77(4):1241-1253. doi: 10.1111/biom.13375. Epub 2020 Sep 28.","Hejazi NS","Biometrics","2021","2020/09/19","PMC8016405","NIHMS1683482","10.1111/biom.13375"
"26509226","STARD 2015: An Updated List of Essential Items for Reporting Diagnostic Accuracy Studies","Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, Lijmer JG, Moher D, Rennie D, de Vet HC, Kressel HY, Rifai N, Golub RM, Altman DG, Hooft L, Korevaar DA, Cohen JF; STARD Group.","Radiology. 2015 Dec;277(3):826-32. doi: 10.1148/radiol.2015151516. Epub 2015 Oct 28.","Bossuyt PM","Radiology","2015","2015/10/29","","","10.1148/radiol.2015151516"
"31999736","Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans","Zhao LP, Fiore-Gartland A, Carpp LN, Cohen KW, Rouphael N, Fleurs L, Dintwe O, Zhao M, Moodie Z, Fong Y, Garrett N, Huang Y, Innes C, Janes HE, Lazarus E, Michael NL, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Robb ML, De Rosa SC, Corey L, Gray GE, Seaton KE, Yates NL, McElrath MJ, Frahm N, Tomaras GD, Gilbert PB.","PLoS One. 2020 Jan 30;15(1):e0226803. doi: 10.1371/journal.pone.0226803. eCollection 2020.","Zhao LP","PLoS One","2020","2020/01/31","PMC6992005","","10.1371/journal.pone.0226803"
"27001493","Early-Phase Studies of Biomarkers: What Target Sensitivity and Specificity Values Might Confer Clinical Utility?","Pepe MS, Janes H, Li CI, Bossuyt PM, Feng Z, Hilden J.","Clin Chem. 2016 May;62(5):737-42. doi: 10.1373/clinchem.2015.252163. Epub 2016 Mar 21.","Pepe MS","Clin Chem","2016","2016/03/23","PMC5003106","NIHMS810060","10.1373/clinchem.2015.252163"
"28819063","STARD for Abstracts: essential items for reporting diagnostic accuracy studies in journal or conference abstracts","Cohen JF, Korevaar DA, Gatsonis CA, Glasziou PP, Hooft L, Moher D, Reitsma JB, de Vet HC, Bossuyt PM; STARD Group.","BMJ. 2017 Aug 17;358:j3751. doi: 10.1136/bmj.j3751.","Cohen JF","BMJ","2017","2017/08/19","","","10.1136/bmj.j3751"
"28131393","Predictors of durable immune responses six months after the last vaccination in preventive HIV vaccine trials","Huang Y, Zhang L, Janes H, Frahm N, Isaacs A, Kim JH, Montefiori D, McElrath MJ, Tomaras GD, Gilbert PB.","Vaccine. 2017 Feb 22;35(8):1184-1193. doi: 10.1016/j.vaccine.2016.09.053. Epub 2017 Jan 25.","Huang Y","Vaccine","2017","2017/01/30","PMC5319823","NIHMS842454","10.1016/j.vaccine.2016.09.053"
"21320940","Measuring the performance of markers for guiding treatment decisions","Janes H, Pepe MS, Bossuyt PM, Barlow WE.","Ann Intern Med. 2011 Feb 15;154(4):253-9. doi: 10.7326/0003-4819-154-4-201102150-00006.","Janes H","Ann Intern Med","2011","2011/02/16","PMC3085402","NIHMS285098","10.7326/0003-4819-154-4-201102150-00006"
"27846073","Brief Report: Preventing HIV-1 Infection in Women Using Oral Preexposure Prophylaxis: A Meta-analysis of Current Evidence","Hanscom B, Janes HE, Guarino PD, Huang Y, Brown ER, Chen YQ, Hammer SM, Gilbert PB, Donnell DJ.","J Acquir Immune Defic Syndr. 2016 Dec 15;73(5):606-608. doi: 10.1097/QAI.0000000000001160.","Hanscom B","J Acquir Immune Defic Syndr","2016","2016/11/16","PMC5175411","NIHMS809310","10.1097/QAI.0000000000001160"
"21411493","Strengthening the reporting of genetic risk prediction studies: the GRIPS statement","Janssens AC, Ioannidis JP, van Duijn CM, Little J, Khoury MJ; GRIPS Group.","BMJ. 2011 Mar 16;342:d631. doi: 10.1136/bmj.d631.","Janssens AC","BMJ","2011","2011/03/18","PMC3175742","","10.1136/bmj.d631"
"21423587","Strengthening the reporting of Genetic RIsk Prediction Studies: the GRIPS Statement","Janssens AC, Ioannidis JP, van Duijn CM, Little J, Khoury MJ; GRIPS Group.","PLoS Med. 2011 Mar;8(3):e1000420. doi: 10.1371/journal.pmed.1000420. Epub 2011 Mar 15.","Janssens AC","PLoS Med","2011","2011/03/23","PMC3058100","","10.1371/journal.pmed.1000420"
"36895286","Kinetics of the Antibody Response to Symptomatic SARS-CoV-2 Infection in Vaccinated and Unvaccinated Individuals in the Blinded Phase of the mRNA-1273 COVID-19 Vaccine Efficacy Trial","Follmann D, Janes HE, Chu E, Jayashankar L, Petropoulos CJ, Serebryannyy L, Carroll R, Jean-Baptiste N, Narpala S, Lin BC, McDermott A, Novak RM, Graciaa DS, Rolsma S, Magaret CA, Doria-Rose N, Corey L, Neuzil KM, Pajon R, Miller JM, Donis RO, Koup RA, Baden LR, El Sahly HM.","Open Forum Infect Dis. 2023 Feb 13;10(3):ofad069. doi: 10.1093/ofid/ofad069. eCollection 2023 Mar.","Follmann D","Open Forum Infect Dis","2023","2023/03/10","PMC9991588","","10.1093/ofid/ofad069"
"34330945","COVID-19 vaccines that reduce symptoms but do not block infection need higher coverage and faster rollout to achieve population impact","Swan DA, Bracis C, Janes H, Moore M, Matrajt L, Reeves DB, Burns E, Donnell D, Cohen MS, Schiffer JT, Dimitrov D.","Sci Rep. 2021 Jul 30;11(1):15531. doi: 10.1038/s41598-021-94719-y.","Swan DA","Sci Rep","2021","2021/07/31","PMC8324774","","10.1038/s41598-021-94719-y"
"31434737","Fc Gamma Receptor Polymorphisms Modulated the Vaccine Effect on HIV-1 Risk in the HVTN 505 HIV Vaccine Trial","Li SS, Gilbert PB, Carpp LN, Pyo CW, Janes H, Fong Y, Shen X, Neidich SD, Goodman D, deCamp A, Cohen KW, Ferrari G, Hammer SM, Sobieszczyk ME, Mulligan MJ, Buchbinder SP, Keefer MC, DeJesus E, Novak RM, Frank I, McElrath MJ, Tomaras GD, Geraghty DE, Peng X.","J Virol. 2019 Oct 15;93(21):e02041-18. doi: 10.1128/JVI.02041-18. Print 2019 Nov 1.","Li SS","J Virol","2019","2019/08/23","PMC6803257","","10.1128/JVI.02041-18"
"21434891","Strengthening the reporting of genetic risk prediction studies: the GRIPS statement","Janssens AC, Ioannidis JP, van Duijn CM, Little J, Khoury MJ; GRIPS Group.","Eur J Clin Invest. 2011 Sep;41(9):1004-9. doi: 10.1111/j.1365-2362.2011.02494.x. Epub 2011 Mar 15.","Janssens AC","Eur J Clin Invest","2011","2011/03/26","","","10.1111/j.1365-2362.2011.02494.x"
"21431409","Strengthening the reporting of genetic risk prediction studies: the GRIPS statement","Janssens AC, Ioannidis JP, van Duijn CM, Little J, Khoury MJ; GRIPS Group.","Eur J Epidemiol. 2011 Apr;26(4):255-9. doi: 10.1007/s10654-011-9552-y.","Janssens AC","Eur J Epidemiol","2011","2011/03/25","PMC3088799","","10.1007/s10654-011-9552-y"
"22822245","Adjusting for covariate effects on classification accuracy using the covariate-adjusted receiver operating characteristic curve","Janes H, Pepe MS.","Biometrika. 2009 Jun;96(2):371-382. doi: 10.1093/biomet/asp002. Epub 2009 Apr 1.","Janes H","Biometrika","2009","2012/07/24","PMC3371718","","10.1093/biomet/asp002"
"27649715","Statistical methods for down-selection of treatment regimens based on multiple endpoints, with application to HIV vaccine trials","Huang Y, Gilbert PB, Fu R, Janes H.","Biostatistics. 2017 Apr 1;18(2):230-243. doi: 10.1093/biostatistics/kxw043.","Huang Y","Biostatistics","2017","2016/09/22","PMC6092735","","10.1093/biostatistics/kxw043"
"18840817","Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design","Pepe MS, Feng Z, Janes H, Bossuyt PM, Potter JD.","J Natl Cancer Inst. 2008 Oct 15;100(20):1432-8. doi: 10.1093/jnci/djn326. Epub 2008 Oct 7.","Pepe MS","J Natl Cancer Inst","2008","2008/10/09","PMC2567415","","10.1093/jnci/djn326"
"31536518","Evaluating the impact of policies recommending PrEP to subpopulations of men and transgender women who have sex with men based on demographic and behavioral risk factors","Janes H, Brown MD, Glidden DV, Mayer KH, Buchbinder SP, McMahan VM, Schechter M, Guanira J, Casapia M.","PLoS One. 2019 Sep 19;14(9):e0222183. doi: 10.1371/journal.pone.0222183. eCollection 2019.","Janes H","PLoS One","2019","2019/09/20","PMC6752862","","10.1371/journal.pone.0222183"
"28818434","Adjusting for covariates in evaluating markers for selecting treatment, with application to guiding chemotherapy for treating estrogen-receptor-positive, node-positive breast cancer","Janes H, Brown MD, Crager MR, Miller DP, Barlow WE.","Contemp Clin Trials. 2017 Dec;63:30-39. doi: 10.1016/j.cct.2017.08.004. Epub 2017 Aug 14.","Janes H","Contemp Clin Trials","2017","2017/08/19","PMC5696084","NIHMS902272","10.1016/j.cct.2017.08.004"
"24829343","Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial","Gartland AJ, Li S, McNevin J, Tomaras GD, Gottardo R, Janes H, Fong Y, Morris D, Geraghty DE, Kijak GH, Edlefsen PT, Frahm N, Larsen BB, Tovanabutra S, Sanders-Buell E, deCamp AC, Magaret CA, Ahmed H, Goodridge JP, Chen L, Konopa P, Nariya S, Stoddard JN, Wong K, Zhao H, Deng W, Maust BS, Bose M, Howell S, Bates A, Lazzaro M, O'Sullivan A, Lei E, Bradfield A, Ibitamuno G, Assawadarachai V, O'Connell RJ, deSouza MS, Nitayaphan S, Rerks-Ngarm S, Robb ML, Sidney J, Sette A, Zolla-Pazner S, Montefiori D, McElrath MJ, Mullins JI, Kim JH, Gilbert PB, Hertz T.","J Virol. 2014 Aug;88(15):8242-55. doi: 10.1128/JVI.01164-14. Epub 2014 May 14.","Gartland AJ","J Virol","2014","2014/05/16","PMC4135964","","10.1128/JVI.01164-14"
"23196933","Have the explosive HIV epidemics in sub-Saharan Africa been driven by higher community viral load?","Abu-Raddad LJ, Barnabas RV, Janes H, Weiss HA, Kublin JG, Longini IM Jr, Wasserheit JN; HIV Viral Load Working Group.","AIDS. 2013 Mar 27;27(6):981-989. doi: 10.1097/QAD.0b013e32835cb927.","Abu-Raddad LJ","AIDS","2013","2012/12/01","PMC3725236","NIHMS487763","10.1097/QAD.0b013e32835cb927"
"25190512","Characterizing expected benefits of biomarkers in treatment selection","Huang Y, Laber EB, Janes H.","Biostatistics. 2015 Apr;16(2):383-99. doi: 10.1093/biostatistics/kxu039. Epub 2014 Sep 3.","Huang Y","Biostatistics","2015","2014/09/06","PMC4786637","","10.1093/biostatistics/kxu039"
"17185253","Cox models for ecologic time-series data?","Lumley T, Janes H, Sheppard L.","Environ Health Perspect. 2006 Dec;114(12):A690-1; author reply A691. doi: 10.1289/ehp.114-1764157.","Lumley T","Environ Health Perspect","2006","2006/12/23","PMC1764157","","10.1289/ehp.114-1764157"
"26332672","Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials","Huang Y, Follmann D, Nason M, Zhang L, Huang Y, Mehrotra DV, Moodie Z, Metch B, Janes H, Keefer MC, Churchyard G, Robb ML, Fast PE, Duerr A, McElrath MJ, Corey L, Mascola JR, Graham BS, Sobieszczyk ME, Kublin JG, Robertson M, Hammer SM, Gray GE, Buchbinder SP, Gilbert PB.","PLoS One. 2015 Sep 2;10(9):e0136626. doi: 10.1371/journal.pone.0136626. eCollection 2015.","Huang Y","PLoS One","2015","2015/09/03","PMC4558095","","10.1371/journal.pone.0136626"
"27247223","Assessing the Clinical Impact of Risk Prediction Models With Decision Curves: Guidance for Correct Interpretation and Appropriate Use","Kerr KF, Brown MD, Zhu K, Janes H.","J Clin Oncol. 2016 Jul 20;34(21):2534-40. doi: 10.1200/JCO.2015.65.5654. Epub 2016 May 31.","Kerr KF","J Clin Oncol","2016","2016/06/02","PMC4962736","","10.1200/JCO.2015.65.5654"
"33166790","The association of α4β7 expression with HIV acquisition and disease progression in people who inject drugs and men who have sex with men: Case control studies","Martin AR, Patel EU, Kirby C, Astemborski J, Kirk GD, Mehta SH, Marshall K, Janes H, Clayton A, Corey L, Hammer SM, Sobieszczyk ME, Arthos J, Cicala C, Redd AD, Quinn TC.","EBioMedicine. 2020 Dec;62:103102. doi: 10.1016/j.ebiom.2020.103102. Epub 2020 Nov 7.","Martin AR","EBioMedicine","2020","2020/11/09","PMC7658649","","10.1016/j.ebiom.2020.103102"
"17085745","Insights into latent class analysis of diagnostic test performance","Pepe MS, Janes H.","Biostatistics. 2007 Apr;8(2):474-84. doi: 10.1093/biostatistics/kxl038. Epub 2006 Nov 3.","Pepe MS","Biostatistics","2007","2006/11/07","","","10.1093/biostatistics/kxl038"
"16428259","The optimal ratio of cases to controls for estimating the classification accuracy of a biomarker","Janes H, Pepe M.","Biostatistics. 2006 Jul;7(3):456-68. doi: 10.1093/biostatistics/kxj018. Epub 2006 Jan 20.","Janes H","Biostatistics","2006","2006/01/24","","","10.1093/biostatistics/kxj018"
"19939925","Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies","Seaman MS, Janes H, Hawkins N, Grandpre LE, Devoy C, Giri A, Coffey RT, Harris L, Wood B, Daniels MG, Bhattacharya T, Lapedes A, Polonis VR, McCutchan FE, Gilbert PB, Self SG, Korber BT, Montefiori DC, Mascola JR.","J Virol. 2010 Feb;84(3):1439-52. doi: 10.1128/JVI.02108-09. Epub 2009 Nov 25.","Seaman MS","J Virol","2010","2009/11/27","PMC2812321","","10.1128/JVI.02108-09"
"28199679","Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial","Janes HE, Cohen KW, Frahm N, De Rosa SC, Sanchez B, Hural J, Magaret CA, Karuna S, Bentley C, Gottardo R, Finak G, Grove D, Shen M, Graham BS, Koup RA, Mulligan MJ, Koblin B, Buchbinder SP, Keefer MC, Adams E, Anude C, Corey L, Sobieszczyk M, Hammer SM, Gilbert PB, McElrath MJ.","J Infect Dis. 2017 May 1;215(9):1376-1385. doi: 10.1093/infdis/jix086.","Janes HE","J Infect Dis","2017","2017/02/16","PMC5853653","","10.1093/infdis/jix086"
"29325070","Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial","Fong Y, Shen X, Ashley VC, Deal A, Seaton KE, Yu C, Grant SP, Ferrari G, deCamp AC, Bailer RT, Koup RA, Montefiori D, Haynes BF, Sarzotti-Kelsoe M, Graham BS, Carpp LN, Hammer SM, Sobieszczyk M, Karuna S, Swann E, DeJesus E, Mulligan M, Frank I, Buchbinder S, Novak RM, McElrath MJ, Kalams S, Keefer M, Frahm NA, Janes HE, Gilbert PB, Tomaras GD.","J Infect Dis. 2018 Mar 28;217(8):1280-1288. doi: 10.1093/infdis/jiy008.","Fong Y","J Infect Dis","2018","2018/01/12","PMC6018910","","10.1093/infdis/jiy008"
"29216395","A Randomized Trial Evaluating the Prophylactic Activity of DSM265 Against Preerythrocytic Plasmodium falciparum Infection During Controlled Human Malarial Infection by Mosquito Bites and Direct Venous Inoculation","Murphy SC, Duke ER, Shipman KJ, Jensen RL, Fong Y, Ferguson S, Janes HE, Gillespie K, Seilie AM, Hanron AE, Rinn L, Fishbaugher M, VonGoedert T, Fritzen E, Kappe SH, Chang M, Sousa JC, Marcsisin SR, Chalon S, Duparc S, Kerr N, Möhrle JJ, Andenmatten N, Rueckle T, Kublin JG.","J Infect Dis. 2018 Feb 14;217(5):693-702. doi: 10.1093/infdis/jix613.","Murphy SC","J Infect Dis","2018","2017/12/08","PMC5853383","","10.1093/infdis/jix613"
"17568215","Trends in air pollution and mortality: an approach to the assessment of unmeasured confounding","Janes H, Dominici F, Zeger SL.","Epidemiology. 2007 Jul;18(4):416-23. doi: 10.1097/EDE.0b013e31806462e9.","Janes H","Epidemiology","2007","2007/06/15","","","10.1097/EDE.0b013e31806462e9"
"18477651","Adjusting for covariates in studies of diagnostic, screening, or prognostic markers: an old concept in a new setting","Janes H, Pepe MS.","Am J Epidemiol. 2008 Jul 1;168(1):89-97. doi: 10.1093/aje/kwn099. Epub 2008 May 13.","Janes H","Am J Epidemiol","2008","2008/05/15","","","10.1093/aje/kwn099"
"19012957","HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis","McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, Defawe OD, Carter DK, Hural J, Akondy R, Buchbinder SP, Robertson MN, Mehrotra DV, Self SG, Corey L, Shiver JW, Casimiro DR; Step Study Protocol Team.","Lancet. 2008 Nov 29;372(9653):1894-1905. doi: 10.1016/S0140-6736(08)61592-5. Epub 2008 Nov 13.","McElrath MJ","Lancet","2008","2008/11/18","PMC2774110","NIHMS109576","10.1016/S0140-6736(08)61592-5"
"19017593","Assessing the value of risk predictions by using risk stratification tables","Janes H, Pepe MS, Gu W.","Ann Intern Med. 2008 Nov 18;149(10):751-60. doi: 10.7326/0003-4819-149-10-200811180-00009.","Janes H","Ann Intern Med","2008","2008/11/20","PMC3091826","NIHMS285092","10.7326/0003-4819-149-10-200811180-00009"
"17679623","Letter by Pepe et al regarding article, ""Use and misuse of the receiver operating characteristic curve in risk prediction""","Pepe MS, Janes H, Gu JW.","Circulation. 2007 Aug 7;116(6):e132; author reply e134. doi: 10.1161/CIRCULATIONAHA.107.709253.","Pepe MS","Circulation","2007","2007/08/08","","","10.1161/CIRCULATIONAHA.107.709253"
"15546133","Overlap bias in the case-crossover design, with application to air pollution exposures","Janes H, Sheppard L, Lumley T.","Stat Med. 2005 Jan 30;24(2):285-300. doi: 10.1002/sim.1889.","Janes H","Stat Med","2005","2004/11/17","","","10.1002/sim.1889"
"22952672","MRKAd5 HIV-1 Gag/Pol/Nef vaccine-induced T-cell responses inadequately predict distance of breakthrough HIV-1 sequences to the vaccine or viral load","Janes H, Frahm N, DeCamp A, Rolland M, Gabriel E, Wolfson J, Hertz T, Kallas E, Goepfert P, Friedrich DP, Corey L, Mullins JI, McElrath MJ, Gilbert P.","PLoS One. 2012;7(8):e43396. doi: 10.1371/journal.pone.0043396. Epub 2012 Aug 27.","Janes H","PLoS One","2012","2012/09/07","PMC3428369","","10.1371/journal.pone.0043396"
"24695044","An approach to evaluating and comparing biomarkers for patient treatment selection","Janes H, Brown MD, Huang Y, Pepe MS.","Int J Biostat. 2014;10(1):99-121. doi: 10.1515/ijb-2012-0052.","Janes H","Int J Biostat","2014","2014/04/04","PMC4341986","NIHMS663213","10.1515/ijb-2012-0052"
"23811760","A framework for evaluating markers used to select patient treatment","Janes H, Pepe MS, Huang Y.","Med Decis Making. 2014 Feb;34(2):159-67. doi: 10.1177/0272989X13493147. Epub 2013 Jun 27.","Janes H","Med Decis Making","2014","2013/07/02","PMC3818438","NIHMS508587","10.1177/0272989X13493147"
"21860356","Impact of herpes simplex virus type 2 on HIV-1 acquisition and progression in an HIV vaccine trial (the Step study)","Barnabas RV, Wasserheit JN, Huang Y, Janes H, Morrow R, Fuchs J, Mark KE, Casapia M, Mehrotra DV, Buchbinder SP, Corey L; NIAID HIV Vaccine Trials Network.","J Acquir Immune Defic Syndr. 2011 Jul 1;57(3):238-44. doi: 10.1097/QAI.0b013e31821acb5.","Barnabas RV","J Acquir Immune Defic Syndr","2011","2011/08/24","PMC3446850","NIHMS349902","10.1097/QAI.0b013e31821acb5"
"16222160","Case-crossover analyses of air pollution exposure data: referent selection strategies and their implications for bias","Janes H, Sheppard L, Lumley T.","Epidemiology. 2005 Nov;16(6):717-26. doi: 10.1097/01.ede.0000181315.18836.9d.","Janes H","Epidemiology","2005","2005/10/14","","","10.1097/01.ede.0000181315.18836.9d"
"37440227","Clinical and Demographic Factors Associated With COVID-19, Severe COVID-19, and SARS-CoV-2 Infection in Adults: A Secondary Cross-Protocol Analysis of 4 Randomized Clinical Trials","Theodore DA, Branche AR, Zhang L, Graciaa DS, Choudhary M, Hatlen TJ, Osman R, Babu TM, Robinson ST, Gilbert PB, Follmann D, Janes H, Kublin JG, Baden LR, Goepfert P, Gray GE, Grinsztejn B, Kotloff KL, Gay CL, Leav B, Miller J, Hirsch I, Sadoff J, Dunkle LM, Neuzil KM, Corey L, Falsey AR, El Sahly HM, Sobieszczyk ME, Huang Y; COVID-19 Prevention Network (CoVPN).","JAMA Netw Open. 2023 Jul 3;6(7):e2323349. doi: 10.1001/jamanetworkopen.2023.23349.","Theodore DA","JAMA Netw Open","2023","2023/07/13","PMC10346130","","10.1001/jamanetworkopen.2023.23349"
"21414753","Strengthening the reporting of Genetic RIsk Prediction Studies (GRIPS): explanation and elaboration","Janssens AC, Ioannidis JP, Bedrosian S, Boffetta P, Dolan SM, Dowling N, Fortier I, Freedman AN, Grimshaw JM, Gulcher J, Gwinn M, Hlatky MA, Janes H, Kraft P, Melillo S, O'Donnell CJ, Pencina MJ, Ransohoff D, Schully SD, Seminara D, Winn DM, Wright CF, van Duijn CM, Little J, Khoury MJ.","J Clin Epidemiol. 2011 Aug;64(8):e1-e22. doi: 10.1016/j.jclinepi.2011.02.003. Epub 2011 Mar 16.","Janssens AC","J Clin Epidemiol","2011","2011/03/19","","","10.1016/j.jclinepi.2011.02.003"
"18223484","Fine particulate matter and mortality: a comparison of the six cities and American Cancer Society cohorts with a medicare cohort","Eftim SE, Samet JM, Janes H, McDermott A, Dominici F.","Epidemiology. 2008 Mar;19(2):209-16. doi: 10.1097/EDE.0b013e3181632c09.","Eftim SE","Epidemiology","2008","2008/01/29","","","10.1097/EDE.0b013e3181632c09"
"31601541","Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial","Pantaleo G, Janes H, Karuna S, Grant S, Ouedraogo GL, Allen M, Tomaras GD, Frahm N, Montefiori DC, Ferrari G, Ding S, Lee C, Robb ML, Esteban M, Wagner R, Bart PA, Rettby N, McElrath MJ, Gilbert PB, Kublin JG, Corey L; NIAID HIV Vaccine Trials Network.","Lancet HIV. 2019 Nov;6(11):e737-e749. doi: 10.1016/S2352-3018(19)30262-0. Epub 2019 Oct 7.","Pantaleo G","Lancet HIV","2019","2019/10/12","PMC7156919","","10.1016/S2352-3018(19)30262-0"
"21403077","Strengthening the reporting of genetic risk prediction studies: The GRIPS Statement","Janssens AC, Ioannidis JP, van Duijn CM, Little J, Khoury MJ; GRIPS Group.","Ann Intern Med. 2011 Mar 15;154(6):421-5. doi: 10.7326/0003-4819-154-6-201103150-00008.","Janssens AC","Ann Intern Med","2011","2011/03/16","","","10.7326/0003-4819-154-6-201103150-00008"
"18922395","Statistical analysis of air pollution panel studies: an illustration","Janes H, Sheppard L, Shepherd K.","Ann Epidemiol. 2008 Oct;18(10):792-802. doi: 10.1016/j.annepidem.2008.06.004.","Janes H","Ann Epidemiol","2008","2008/10/17","","","10.1016/j.annepidem.2008.06.004"
"23524037","Re: ""Clinical usefulness of the Framingham cardiovascular risk profile beyond its statistical performance: the Tehran Lipid and Glucose Study""","Janes H, Pepe M.","Am J Epidemiol. 2013 Apr 15;177(8):864-5. doi: 10.1093/aje/kwt043. Epub 2013 Mar 22.","Janes H","Am J Epidemiol","2013","2013/03/26","PMC3668426","","10.1093/aje/kwt043"
"23597282","In pursuit of an HIV vaccine: designing efficacy trials in the context of partially effective nonvaccine prevention modalities","Janes H, Gilbert P, Buchbinder S, Kublin J, Sobieszczyk ME, Hammer SM.","AIDS Res Hum Retroviruses. 2013 Nov;29(11):1513-23. doi: 10.1089/aid.2012.0385. Epub 2013 Jun 25.","Janes H","AIDS Res Hum Retroviruses","2013","2013/04/20","PMC3809388","","10.1089/aid.2012.0385"
"17501939","Matching in studies of classification accuracy: implications for analysis, efficiency, and assessment of incremental value","Janes H, Pepe MS.","Biometrics. 2008 Mar;64(1):1-9. doi: 10.1111/j.1541-0420.2007.00823.x. Epub 2007 May 14.","Janes H","Biometrics","2008","2007/05/16","","","10.1111/j.1541-0420.2007.00823.x"
"24889787","Rejoinder: Combining biomarkers to optimize patient treatment recommendations","Kang C, Janes H, Huang Y.","Biometrics. 2014 Sep;70(3):719-20. doi: 10.1111/biom.12192. Epub 2014 May 30.","Kang C","Biometrics","2014","2014/06/04","PMC4247994","NIHMS636414","10.1111/biom.12192"
"24384634","Understanding HIV epidemics: aggregate viral load metrics and 'smoking guns'","Abu-Raddad LJ, Barnabas RV, Janes H, Weiss HA, Kublin JG, Longini IM Jr, Wasserheit JN.","AIDS. 2013 Nov 13;27(17):2826-7. doi: 10.1097/QAD.0000000000000002.","Abu-Raddad LJ","AIDS","2013","2014/01/04","","","10.1097/QAD.0000000000000002"
"15951711","Do subject characteristics modify the effects of particulate air pollution on daily mortality among the elderly?","Janes H, Sheppard L, Lumley T.","J Occup Environ Med. 2005 Jun;47(6):543; author reply 543-5. doi: 10.1097/01.jom.0000163606.63666.9e.","Janes H","J Occup Environ Med","2005","2005/06/14","","","10.1097/01.jom.0000163606.63666.9e"
"21414754","Strengthening the reporting of Genetic RIsk Prediction Studies: the GRIPS Statement","Janssens AC, Ioannidis JP, van Duijn CM, Little J, Khoury MJ; GRIPS Group.","J Clin Epidemiol. 2011 Aug;64(8):843-7. doi: 10.1016/j.jclinepi.2011.02.004. Epub 2011 Mar 16.","Janssens AC","J Clin Epidemiol","2011","2011/03/19","","","10.1016/j.jclinepi.2011.02.004"
"21406688","Strengthening the reporting of genetic risk prediction studies: the GRIPS statement","Janssens AC, Ioannidis JP, van Duijn CM, Little J, Khoury MJ; GRIPS Group.","Circ Cardiovasc Genet. 2011 Apr;4(2):206-9. doi: 10.1161/CIRCGENETICS.111.959668. Epub 2011 Mar 15.","Janssens AC","Circ Cardiovasc Genet","2011","2011/03/17","","","10.1161/CIRCGENETICS.111.959668"
"15568185","Identifying target populations for screening or not screening using logic regression","Janes H, Pepe M, Kooperberg C, Newcomb P.","Stat Med. 2005 May 15;24(9):1321-38. doi: 10.1002/sim.2021.","Janes H","Stat Med","2005","2004/11/30","","","10.1002/sim.2021"
